Celgene has finalised the purchase of US-based biopharmaceutical firm Juno Therapeutics for approximately $9bn, amounting to $87 per share.

The companies signed a definitive merger agreement in January 2018 intended to boost Celgene’s position in the haematology market and provide required support for the growth of Juno.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The deal will advance Celgene’s cellular manufacturing capabilities and add new technologies to its portfolio, putting it at the forefront of the cellular immunotherapy market.

Celgene chairman and CEO of Mark Alles said: “Our colleagues at Juno are developing some of the most promising approaches to treating cancer, and we are excited to add their pioneering work to Celgene’s leading haematology and oncology research and commercial platform.

“Together, we expect to expand our opportunities to discover and develop new therapies that will improve and extend the lives of patients worldwide.”

“Together, we expect to expand our opportunities to discover and develop new therapies that will improve and extend the lives of patients worldwide.”

The acquisition will expand Celgene’s lymphoma programme by providing complete global rights to Juno’s CD-19 targeted CAR T therapy, JCAR017 (lisocabtagene maraleucel; liso-cel).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The CAR T drug candidate is being developed to treat relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL) and is expected to gain US regulatory approval in 2019.

JCAR017 is expected to be a growth driver from 2020, bringing in global peak sales of about $3bn.

Celgene also plans to use Juno’s research and development facility in Seattle and its manufacturing facility in Bothell, Washington to expand its existing centre of excellence for immuno-oncology translational medicine.